Breast Pathology
Aiat Shaban Hemida; Reham Ahmed Abdelaziz; Moshira Mohammed Abd El-Wahed; Nancy Youssef Asaad; Marwa Mohammed Serag El-Edien; Hend Ali Elshahat
Abstract
Background & Objective: The regulator of chromosome condensation 2 (RCC2) and RAS-related C3 botulinum toxin substrate 1 (Rac1) have been implicated in the promotion of breast cancer cell proliferation and migration. The signaling pathway involving p53/RCC2/Rac1 has been proposed to contribute to ...
Read More
Background & Objective: The regulator of chromosome condensation 2 (RCC2) and RAS-related C3 botulinum toxin substrate 1 (Rac1) have been implicated in the promotion of breast cancer cell proliferation and migration. The signaling pathway involving p53/RCC2/Rac1 has been proposed to contribute to the regulation of colon cancer metastasis. However, until now, this pathway has not been thoroughly investigated in breast cancer. This study seeks to explore the influence of immunohistochemical expression and the correlation among RCC2, Rac1, and p53 in breast infiltrating ductal carcinoma (IDC).Methods: Immunostaining was performed on 120 breast IDC specimens using RCC2, Rac1, and p53 antibodies. Statistical analyses were conducted to examine the correlations between these antibodies.Results: A Positive expression of RCC2, Rac1, and p53 was observed in 116 (96.7%), 120 (100%), and 33 (27.5%) of the breast cancer cases, respectively. RCC2, Rac1, and p53 demonstrated association with poor prognostic parameters such as frequent mitoses, high Ki-67 status, positive lymphovascular invasion (LVI), and advanced tumor stage. A highly significant direct correlation was found between each immunohistochemical marker and the other two markers. Shorter overall survival was linked to multifocal tumors (P=0.017), advanced tumor stage (T3) (P=0.010), Luminal B subtype (P=0.015), progressive disease (P=0.003), positive Her2neu status (P=0.008), and metastasis to distant organs (P<0.001). However, RCC2, Rac1, and p53 did not exhibit a significant association with overall survival.Conclusion: The high expression levels of RCC2, Rac1, and p53 in breast IDC suggest their potential role in tumor behavior. The association of RCC2 and Rac1 with poor prognostic parameters may serve as predictive indicators for aggressive tumors, thus implying that targeted therapy could be beneficial in the treatment of breast cancer.
Hematopathology
Alireza Rezvani; Ahmad Monabati; Zahra Kargar; Akbar Safaie; Mahdi Mahmoodzadeh; Hamideh Moosapour; Marzieh Hosseini; Soleiman Kheiri; Elham Taheri
Abstract
Background & Objective: Some of the patients with myelodysplastic syndrome (MDS) are categorized as good prognosis based on the Revised International Prognostic Scoring System (IPSS-R). However, these patients may have poor clinical outcomes. It seems that the current diagnostic tools and IPSS-R ...
Read More
Background & Objective: Some of the patients with myelodysplastic syndrome (MDS) are categorized as good prognosis based on the Revised International Prognostic Scoring System (IPSS-R). However, these patients may have poor clinical outcomes. It seems that the current diagnostic tools and IPSS-R cannot consider genetic factors for determining the prognosis of MDS patients.Methods: This cross-sectional study included all adult MDS patients of both genders who were admitted from March 2015 to March 2020 to the Hematology wards of two educational tertiary hospitals in Iran (Namazi and Faghihi, affiliated with Shiraz University of Medical Sciences). Study data included relevant retrospective data from medical records and the results of immunohistochemical p53 staining on bone marrow biopsies.Results: Of the 84 patients, 65 (77.4%) showed p53 expression in bone marrow. They had shorter median survival than those without p53 expression. Considering both variables of P53 IHC results and IPSS-R score, the patients who died with low-risk IPSS-R score presented high p53 expression.Conclusion: This study shows that the investigation of p53 expression by IHC at the time of diagnosis is a valuable indicator of survival rate in MDS patients. These data suggest that the immunohistochemical analysis of p53 can be a prognostic tool for MDS and should be used as an adjunct test to make decisions on the best therapeutic choice.
Mehdi Seilanian Toosi; Mohammad Reza Ghavam Nasiri; Kamran Ghafarzadegan; Azar Fani Pakdel; Roham Salek; Kazem Anvari
Volume 3, Issue 1 , January 2008, , Pages 5-10
Abstract
Background and Objective: P53 is a suppressive gene that plays a key role in DNA repair and apoptosis. The purpose of this study was to investigate the effect of P53 protein over-expression and some clinicopathological factors on the esophageal squamous cell carcinoma (SCC) response to neoadjuvant chemoradiotherapy. ...
Read More
Background and Objective: P53 is a suppressive gene that plays a key role in DNA repair and apoptosis. The purpose of this study was to investigate the effect of P53 protein over-expression and some clinicopathological factors on the esophageal squamous cell carcinoma (SCC) response to neoadjuvant chemoradiotherapy. Patients and Methods: In this retrospective cohort study, 44 patients with localized esophageal SCC undergoing neoadjuvant chemoradiotherapy (cisplatin + 5FU and 40 Gy in 20 fractions of irradiation) and surgery were evaluated. Pretreatment specimens were immunohistochemically assessed for p53 over-expression and scored according to the frequency of stained cells. The pathologic response in resected specimens was categorized as follows: complete response (CR), no evidence of malignant cell; partial response (PR), small foci of malignant cells and negative lymph nodes and minor response, macroscopic residual tumor or positive lymph nodes. Results: It was found out that p53 protein over-expression exists in 29 cases (65.9%). Following chemoradiotherapy, CR and PR were found in 9 (20.5%) and 19 cases (43.2%) respectively. There were also no significant association between tumor response and clinicopathological features such as sex (p = 1), age (p = 0.82), dysphagia grade (p = 0.82) and longitudinal length of the tumor (p = 0.59). No significant correlation was found between p53 expression and pathological response to preoperative chemoradiotherapy (p = 0.94). Conclusion: These findings suggest that p53 protein expression is not reliable for predicting the response to neoadjuvant chemoradiotherapy. There were also no correlations between pathological response to chemoradiotherapy and clinical features such as age, sex, dysphagia grade and longitudinal diameter of the tumor.
